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Objective: We sought to examine the diagnostic utility of existing predictors of any hemorrhagic transformation
(HT) and compare them with new perfusion imaging permeability measures in ischemic stroke patients receiving
alteplase only.
Methods: A pixel-based analysis of pretreatment CT perfusion (CTP) was undertaken to define the optimal CTP perme-
ability thresholds to predict the likelihood of HT. We then compared previously proposed predictors of HT using
regression analyses and receiver operating characteristic curve analysis to produce an area under the curve (AUC). We
compared AUCs using χ2 analysis.
Results: From 5 centers, 1,407 patients were included in this study; of these, 282 had HT. The cohort was split into a
derivation cohort (1,025, 70% patients) and a validation cohort (382 patients or 30%). The extraction fraction (E) perme-
ability map at a threshold of 30% relative to contralateral had the highest AUC at predicting any HT (derivation AUC
0.85, 95% confidence interval [CI], 0.79–0.91; validation AUC 0.84, 95% CI 0.77–0.91). The AUC improved when perme-
ability was assessed within the acute perfusion lesion for the E maps at a threshold of 30% (derivation AUC 0.91, 95%
CI 0.86–0.95; validation AUC 0.89, 95% CI 0.86–0.95). Previously proposed associations with HT and parenchymal
hematoma showed lower AUC values than the permeability measure.
Interpretation: In this large multicenter study, we have validated a highly accurate measure of HT prediction. This mea-




Symptomatic intracranial hemorrhage or hemorrhagic
transformation (HT) occurs spontaneously after ischemic
stroke. There are few useful predictive markers in clinical
practice to identify which patients are at the highest risk
of HT. HT ranges from hemorrhagic infarction (HI),
which may be a marker of successful reperfusion with
minimal or no clinical impact,1 to large parenchymal
hematoma (PH), which substantially increases the risk of
poor outcome, including death.2 Treatment with alteplase
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is associated with a substantially increased risk of HT from
2.4 to 27%,3 but this risk is balanced against a higher
chance of improved clinical outcomes in appropriately
selected patients.4–6 A means of accurately predicting
which patients may or may not be at risk of PH or symp-
tomatic intracranial hemorrhage could have significant
clinical implications and better inform the treatment
decision-making process.
Vascular permeability can be measured with mag-
netic resonance imaging (MRI) or computed tomography
perfusion (CTP)7 by measuring the rate of contrast leaving
a voxel, with the assumption being that a slower or
reduced contrast outflow (compared with inflow) is attrib-
utable to elevated blood vessel permeability. Elevated per-
meability may represent disruption or “leakiness” of the
blood–brain barrier (BBB), where contrast becomes
trapped in the BBB or leaks into the surrounding tissue.
Permeability is quantified by analysis of dynamic contrast-
enhanced images (unprocessed perfusion imaging maps
showing contrast flow) to observe decreases in hydrostatic
gradients between blood vessels and brain tissue, which
can result in contrast lingering around blood vessels. Per-
meability measures reflect a complex interaction between
several physiological variables that affect contrast leakage,
such as edema, mass effect, transmural pressure, interstitial
fluid pressure, and abnormal tissue biomechanical proper-
ties related to BBB permeability. For example, tissue blood
volume is associated with abnormal BBB permeability, and
several studies have observed a link between decreased cere-
bral blood volume (CBV) and increased BBB permeability.
This is relevant because CBV has been proposed as a
marker of increased hemorrhage risk. Permeability maps
generated from magnetic resonance perfusion-weighted
imaging (PWI) and computed tomography perfusion
(CTP) have previously been proposed as measures to pre-
dict HT8,9 owing to the proposed relation between perme-
ability maps and blood vessel integrity. However, the
accuracy or clinical usefulness of permeability imaging is
not yet clear, and there are multiple permutations of perme-
ability measures.10 However, there is evidence suggesting
that BBB permeability11,12 can increase in the first few
hours after stroke and that elevated permeability measured
on CTP might indicate ischemia-induced vascular dam-
age13 and serve as a marker to predict HT.14
Previous studies have identified a plethora of clinical
risk factors for HT, including advancing age, stroke sever-
ity, pretreatment hypertension, and concurrent use of
antithrombotic agents. In addition, other studies have
identified imaging and laboratory markers, such as hyper-
glycemia, thrombocytopenia, extensive early ischemic
changes on computed tomography (CT), the hyperdense
middle cerebral artery sign, very low cerebral blood flow
lesion volume, severely delayed blood flow, and large
ischemic core volume, which have been related to HT
events.15–18 However, apart perhaps from major early
ischemic change (which is a poor prognostic marker
irrespective of HT), none as yet has translated into clinical
practice as a routinely used predictor of hemorrhagic
transformation. In the present study, we sought to assess
the diagnostic utility and association of permeability mea-
sures acquired with acute CTP and to identify the optimal
cut points for HT outcome in ischemic stroke patients.
Next, we sought to compare previously proposed markers
of HT with CTP permeability imaging and to assess the
comparative accuracies in a large multicenter dataset. We
hypothesised that permeability imaging would be an accu-
rate measure of HT of equal or greater value to other vali-
dated markers of HT prediction.
Patients and Methods
Consecutive acute ischemic stroke patients presenting to
hospital within 4.5 hours of symptom onset at 5 centers
(John Hunter Hospital, New South Wales, Australia; Box
Hill Hospital, Melbourne, Victoria, Australia; Royal Ade-
laide Hospital, Adelaide, South Australia, Australia;
Huashan Hospital, Shanghai, China; and Sunnybrook
Health Science Centre, Toronto, Ontario, Canada)
between 2011 and 2016 were recruited prospectively for
the INternational Stroke Perfusion Imaging REgistry
(INSPIRE). As part of the registry, patients underwent
baseline multimodal CT imaging with non-contrast CT,
CTP, and follow-up imaging with MRI or CT at 24 hours
post-stroke. Clinical stroke severity was assessed at the two
imaging time points using the National Institutes of Health
Stroke Scale (NIHSS). All patients in this study were
treated with intravenous thrombolysis according to local
guidelines and at the clinical judgement of the treating phy-
sician. The modified Rankin scale (mRS) was assessed
90 days after stroke. Thrombectomy cases were excluded
from this study. Written informed consent was obtained
from all participants, and the INSPIRE study was approved
by the local ethics committees.
Acute Multimodal CT Protocol
Participants recruited at John Hunter Hospital and Royal
Adelaide Hospital were scanned using a Toshiba Aquilion
320-slice CT scanner (Toshiba Medical Systems, Tokyo,
Japan). A total of 19 acquisitions occurred in 60 seconds.
Forty milliliters of contrast agent (Ultravist 370; Bayer
HealthCare, Berlin, Germany) was injected at 6ml/s,
followed by 30ml of saline. Participants recruited at Box
Hill Hospital were scanned using a 64-detector GE
lightspeed (GE Healthcare, Waukesha, WI). A total of
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19 acquisitions occurred in 54 seconds. Forty-five millili-
ters of contrast agent (Ultravist 370; Bayer HealthCare,
Berlin, Germany) was injected at 6ml/s. Participants rec-
ruited at Huashan Hospital were scanned using a Bril-
liance iCT 126-slice CT scanner (Philips Medical
Systems, Cleveland, OH). A total of 23 acquisitions
occurred in 60 seconds. Forty milliliters of the same con-
trast was injected at 5ml/s, followed by 20ml of saline.
Participants recruited at Sunnybrook Health Sciences
Center underwent an acute CT with a 64-row CT scanner
(GE Healthcare, Waukesha, WI). Baseline and 24 hour
CT angiogram parameters were as follows: 0.7ml/kg
iodinated contrast agent up to a maximum of 90ml
(Omnipaque 300mg iodine/ml; GE Healthcare,
Piscataway, NJ); 5–10 second delay; 120kVp; 270mA;
rotation, 1 second; 1.25-mm-thick sections; table speed,
20.62mm per rotation. Biphasic CT perfusion protocol
from basal ganglia to the lateral ventricles: 80kVp;
150mA; collimation, 8 × 5 mm; rotation, 1 second for
45 seconds followed by 6 further acquisitions 15 seconds
apart for a total of 135 seconds. Iodinated contrast agent
0.5ml/kg (maximum 50ml) at 4ml/s was administered
5 seconds before the start of the sequence. All acute perfu-
sion imaging acquired 60mm or more of coverage.
Twenty-four Hour Imaging Protocol
As close as possible to 24 hours after acute imaging, all
patients, regardless of treatment, underwent a stroke MRI
protocol on a 1.5 or 3T scanner (Siemens Avanto or
Verio). The magnetic resonance (MR) protocol included:
diffusion-weighted imaging (DWI), perfusion-weighted
imaging (PWI), MR time-of-flight angiography (MRA),
and fluid-attenuated inversion recovery (FLAIR) imaging.
For those with a contraindication to MRI, repeat non-
contrast CT (NCCT) and CTP was performed using the
above protocols.
Imaging Analysis
All perfusion imaging was post-processed with the com-
mercial software MIStar (Apollo Medical Imaging Tech-
nology, Melbourne, Victoria, Australia). Acute perfusion
imaging was processed using single value deconvolution
with delay and dispersion correction.19 Areas of no blood
flow, chronic infarction or cerebrospinal fluid regions were
masked from the perfusion maps. Pixels with no blood
flow were removed by eliminating areas where cerebral
blood flow = 0, and cerebrospinal fluid/ventricle and skull
pixels were removed using a Hounsfield unit threshold
and geometric analysis. Previously validated thresholds
were applied in order to measure the volume of the acute
perfusion lesion (relative delay time [DT] >3 seconds) and
acute ischemic core (relative cerebral blood flow [CBF]
<30%).20 Penumbral volume was calculated as the volume
of the perfusion deficit (DT threshold >3 seconds) minus
the volume of the ischemic core (relative CBF threshold
<30% within the DT >3 seconds lesion). The volume of
severely hypoperfused tissue (Tmax >14 seconds)21 and
very low CBV (defined as <2.5th percentile of brain con-
tralateral to the infarct)22 was also recorded for use in HT
prediction models.
The 24 hour follow-up MRI and/or CT scans were
read and Heidelberg Bleeding Classification subtypes cat-
egorised by 2 raters (A.B. and M.P.), with any disagree-
ment resolved by a third reader (C.L.). Raters were
blinded to all the other imaging and clinical data.
Reviewers were blinded to all other imaging. The presence
or absence of post-thrombolytic bleeding was then
ascertained on 24 hour imaging. Patients were then
divided into a target group (HT evident) and a negative
HT group. The raters categorised HT in the HT evident
group into eight subtypes based on Heidelberg Bleeding
Classification as: (1a) for hemorrhagic infarction 1 (HI1),
scattered small petechiae, no mass effect; (1b) for HI2,
confluent petechiae, no mass effect; (1c) for parenchymal
hemorrhage 1 (PH1), hematoma within infarcted tissue,
occupying <30%, no substantive mass effect; (2) for PH2,
hematoma occupying ≥30% of the infarcted tissue, with
obvious mass effect; (3a) for parenchymal hematoma
remote from infarcted brain tissue; (3b) for intraventricular
hemorrhage; (3c) for subarachnoid hemorrhage; and (3d)
for subdural hemorrhage.23
Permeability Measures
All permeability measures were performed using MIStar,
and for each patient three permeability maps were gen-
erated. The extraction fraction (E) was calculated as the
fraction of contrast agent removed from the tissue con-
trast enactment curve or input residue function during
the first pass. At t1, the unextracted tracer exits via out-
flowing blood, and the detector response registers the
fraction of extracted tracer, given by E. After t1, the
extracted tracer diffuses back into the blood and is
cleared by outflowing blood, giving rise to a gradually
decreasing parenchymal phase. The parameters that can
be obtained directly from fitting experimental curves t1
are the rate of transfer from intravascular to extravascu-
lar compartment (k21) and rate of transfer from extra-
vascular to intravascular compartment (k12). Formally,
E can be given by:
E = 1−e−k21t1
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which is a function of the vascular transit time, t1. This
expression for E implies that, for two capillaries with the
same outflow (extravasation) rate, k21, the fraction of tracer
extracted in the first pass would be larger for the capillary
with the longer transit time.24–26 The permeability–surface
area product (P × S, often written PS) is the flow of mole-
cules through the capillary membranes in a certain volume
of tissue (expressed in milliliters per minute per 100ml tis-
sue). PS depends not only on the characteristics of the cap-
illary wall, but also on the contrast agent used. PS
represents the total diffusional flux across all capillaries and
is measured in milliliters per minute per 100g of tissue. It
can be interpreted as follows: the unidirectional flux of sol-
utes from blood plasma to the interstitial space is equivalent
to the complete transfer of all the solutes in PS milliliters of
blood per minute to the interstitial space. In the normal
brain parenchyma, BBB is intact and tightly regulated. PS
is normally 0 for large hydrophilic molecules, such as a
peripherally injected iodinated contrast agent. PS is some-
times called Ktrans, but PS corresponds to Ktrans only in very
specific conditions. The assumption that back-flux from
extravascular compartment into the intravascular one can
be neglected during early times depends on the relative
magnitude of blood flow (F) and the capillary PS. Perme-
ability (P) is related to the diffusion coefficient of contrast
agent in the pores of the capillary endothelium, which are
assumed to be water filled. The diffusion flux of contrast
agent across the capillary endothelium is dependent on
both the diffusion coefficient and the total surface area of
the pores or the PS product. The PS product has the same
dimensions as F, and thus the ratio PS/F is dimensionless.
PS is related to K as follows:
K = EF
If PS/F < 1, then K ≈ PS. In normal cerebral vascu-
lature, PS is negligible for all contrast agents presently in
use. The relative magnitude of PS and F also determines
E.27,28 In summary, E is the ratio of contrast leaving a
voxel, as opposed to measures such as CBF or CBV,
which measure contrast inflow.
The transfer constant, Ktrans, is a complex combina-










where Ctissue is the concentration of contrast in the tissue,
Cplasma the concentration of contrast in the plasma,
TTPtissue the time to reach the peak intensity value in the
tissue, and TTPplasma is the time to reach the peak inten-
sity in the plasma in the time–intensity graph for tissue
and plasma, respectively.12
Permeability Analysis
For each of the three “types” of the maps defined above
(E, Ktrans and PS), a voxel-based analysis was performed,
initially with a whole-hemisphere region of interest and
subsequently with the region of interest constrained
within the perfusion lesion to define the “location” class
(set as a threshold of DT >3 seconds). This results in six
individual classes per patient that combine “type” and
“location”. For each of these six classes individually, a rela-
tive threshold at 5% increments (range 0–100%) was
tested, resulting in 20 threshold-specific maps (120 maps
overall per patient).
Threshold-based analysis: In order to identify the
optimal threshold to predict HT, for each of the
120 threshold-specific maps a receiver operating character-
istic (ROC) curve analysis was used to test the predictive
performance of CTP permeability maps at predicting
hemorrhagic outcome for: (1) all HT; (2) only HI;
(3) only PH (PH1 and PH2); and (4) remote hemorrhage.
Results are presented as an area under the curve (AUC)
with 95% confidence intervals (CIs) for the whole ROC
curve for a perfusion map at a single threshold. Specificity,
sensitivity, positive predictive value, and negative predic-
tive value were calculated for each threshold increment
(eg, E, Ktrans, and PS). The optimal thresholds were deter-
mined by the highest AUC. All CTP scans with an acqui-
sition or contrast curve (time from the start of the signal
increase attributable to contrast arrival) of <45 seconds
were excluded from this study owing to the inability to
measure Ktrans and PS accurately from these scans.
Statistical Analysis
Statistical analyses were programmed using Stata v.13.0
(StataCorp Ltd, College Station, TX). Descriptive results
and quantitative baseline patient characteristics were pres-
ented as the mean ± standard deviation (SD) or the
median and interquartile range. Student paired t tests or
Wilcoxon signed-rank tests were performed for parametric
or nonparametric data, respectively.
The study cohort was split into derivation and vali-
dation cohorts for analysis (70 and 30%, respectively),
using stratified sampling to ensure that there were no sig-
nificant differences between the cohorts in terms of base-
line characteristics or the occurrences of HT/PH.
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An ROC curve analysis was used to estimate the
AUC, sensitivity, and specificity of each of the permeability
maps as a prognostic tool for hemorrhagic outcome. In the
ROC analysis, each measurement threshold is a whole anal-
ysis and not a point on an ROC curve. Next, an analysis
was undertaken to identify whether there was a relation
between the volume of the permeability lesion and the Hei-
delberg HT grade, using ordinal logistic regression. Addi-
tionally, patients were analyzed separately based the
location of the hemorrhage (either around the area of
follow-up infarction or remote from the initial ischemia on
CTP). Lastly, once derived, the optimal permeability mea-
sure was again assessed within the validation cohort using
ROC AUC analysis. The validation ROC AUC values are
compared between the pre-specified threshold values to
identify the potentially optimal threshold using χ2 analysis.
Once the optimal cut points to predict HT grade
were determined, a further ROC AUC analysis was per-
formed using previously identified markers of HT grade
(ischemic core volume, very low CBV, Tmax + 14 second
volume, reperfusion, diabetes, and age) and compared
with the optimal permeability AUC using χ2 analysis.
Results
Throughout the study period, the INSPIRE registry col-
lected 2,127 patients who underwent acute CTP imaging
within 4.5 hours of symptom onset and were treated with
intravenous alteplase. From the cohort of 2,127 patients, a
total of 317 were excluded from the study analysis:
154 because they had incomplete clinical data, and
93 because the imaging could not be processed owing to
excessive motion or other technical errors. A further
203 patients were excluded because their acquisition time
was <45 seconds. Of the remaining 1,407 patients, 282
developed HTs (91 HI1/1a, 107 HI2/1b, 51 PH1/1c, and
33 PH2/2, 29 of which were symptomatic). Additionally,
of the 282 HTs, 47 were 3a,b,c remote from the infarct and
235 were involving the infarct. The cohort of 1,407
patients were then split into derivation (1,025 patients,
197 HTs) and validation (382 patients, 85 HTs) cohorts
for subsequent analysis. Lastly, of the included patients,
493 had follow-up MRI rather than CT (77 HTs,
26 HI1/1a, 11 HI2/1b, 23 PH1/1c, and 17 PH2/2).
The baseline characteristics of patients are listed in
Table 1. There were significant differences between the
baseline NIHSS, baseline perfusion lesion volume, baseline
ischemic core volume, and treatment types between
patients with and without any HT at 24 hours. There were
also significant differences in the 24 hour NIHSS, 3 month
mRS, and 24 hour core volume between patients with and
without any HT at 24 hours (Table 1). There were no sig-
nificant differences in the baseline characteristics between
the derivation and validation cohorts (p > 0.05).
TABLE 1. Patient Clinical and Imaging Characteristics
Characteristic
HT, n = 282
(mean, SD)
Non-HT, n = 1,125
(mean, SD) p
Age (yr) 66 (15) 67 (13) 0.422
Time to scanning (min) 105 (49) 99 (51) 0.481
Baseline NIHSS 14 (6) 8 (5) <0.001
Baseline perfusion lesion volume (DT3) (ml) 94 (69) 78 (65) 0.011
Baseline ischemic core volume (CBF 30%) (ml) 42 (43) 22 (17) <0.001
Very low CBV (ml) 6 (9) 3 (7) 0.163
Tmax 14 s volume (ml) 23 (33) 15 (24) 0.107
24 h NIHSS 12 (8) 8 (7) <0.001
90 day mRS 3 (1) 2 (1) <0.001
24 h core volume: all patients (ml) 56 (42) 27 (18) <0.001
24 h core volume: MRI follow-up patients (ml) 38 (21) 19 (11) 0.033
The baseline demographic information was compared between patients with and without a hemorrhagic transformation at 24 h. There were significant
differences between the baseline NIHSS, baseline perfusion lesion volume, baseline ischemic core volume, and treatments. There were also significant
differences in the 24 h NIHSS, 3 mo mRS, and 24 h core volume between study groups. All study patients were treated with intravenous alteplase.
CBF = cerebral blood flow; CBV = cerebral blood volume; mRS = modified Rankin scale; NIHSS = National Institutes of Health Stroke Scale.
470 Volume 88, No. 3
ANNALS of Neurology












E 20 0.82 0.86 0.79 76 0.79 0.067
25 0.84 0.84 0.83 79 0.82 0.187
30 0.85 0.93 0.78 81 0.84 0.038
35 0.83 0.79 0.88 80 0.83 0.073
PS 60 0.74 0.42 0.77 66 <0.7 0.277
65 0.73 0.43 0.68 68 <0.7 0.437
70 0.73 0.32 0.77 71 <0.7 0.394
Ktrans 65 0.74 0.40 0.82 51 <0.7 0.299
70 0.71 0.47 0.85 58 <0.7 0.424
Analysis confined to within the perfusion lesion
E 20 0.89 0.88 0.93 81 0.86 <0.001
25 0.89 0.90 0.93 87 0.86 <0.001
30 0.91 0.90 0.95 91 0.89 <0.001
35 0.88 0.89 0.87 86 0.87 0.031
PS 60 0.71 0.34 0.55 76 0.67 0.387
65 0.70 0.47 0.83 78 0.59 0.211
70 0.73 0.34 0.82 80 0.64 0.347
Ktrans 65 0.75 0.40 0.79 42 0.68 0.427
70 0.74 0.54 0.83 55 0.66 0.447
Each AUC represents the result for the specific threshold tested. The χ2 p value represents the comparison between different thresholds.
AUC = area under the curve.
FIGURE 1: The likelihood of hemorrhagic transformation with the absolute E lesion volume. With increasing E lesion volume,
there was an increased likelihood of hemorrhage and an increase in the severity of hemorrhage.
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The E permeability map of the whole brain at a
threshold of 30% had the highest AUC for predicting any
HT (derivation AUC 0.85, 95% CI 0.79–0.91; validation
AUC 0.84, 95% CI 0.77–0.91; Fig 1 and Table 2). Addi-
tionally, an E permeability map of the whole brain at a
threshold of 20% was also a reasonably strong predictor of
HT (derivation AUC 0.82, 95% CI 0.76–0.88; validation
AUC 0.79). Both the PS and Ktrans maps of the whole
brain were relatively poor predictors of HT overall (PS
AUC 0.62, validation AUC 0.64; Ktrans AUC 0.67, valida-
tion AUC 0.63). Importantly, permeability maps from E,
Ktrans, or PS were not able to predict remote hemorrhage
outside of the acute perfusion lesion in the ipsilesional or
contralesional hemisphere (derivation and validation
p > 0.5), and remote hemorrhages were excluded from
subsequent analyses. These results were maintained in the
cohort of patients with MRI at follow-up (E permeability
30%, AUC 0.83, 95% CI 0.76–0.92; Ktrans AUC <0.6,
p > 0.5; PS AUC <0.6, p > 0.5).
There was an improved AUC for predicting HT
when permeability was restricted to the perfusion lesion
(with a threshold of DT >3 seconds) for the E maps at
thresholds of 30% (derivation AUC 0.91, 95% CI
0.86–0.95; validation AUC 0.89, 95% CI 0.86–0.95;
Fig 2 and Table 2) and 20% (derivation AUC 0.89, 95%
CI 0.83–0.95; validation AUC 0.86). Lastly,
E permeability maps at a threshold of 30% within the per-
fusion lesion were also very accurate at predicting patients
with PH1/1c or PH2/2 (derivation AUC 0.93, 95% CI
0.89–0.96; validation AUC 0.9), whereas the Ktrans and
PS were relatively poor (PS AUC 0.67, validation AUC
0.68; Ktrans AUC 0.66, validation AUC 0.64). An E map
at a threshold of 30% within the perfusion lesion had the
highest overall AUC at predicting HT across all tested
measures (Table 2). Again these results were maintained
in the cohort of patients with MRI at follow-up
(E permeability 30%, AUC 0.89, 95% CI 0.78–0.96;
Ktrans AUC <0.6, p > 0.5; PS AUC <0.6, p > 0.5).
There was a significant association between the vol-
ume of the E permeability map deficit at a threshold of
30% and the severity of the hemorrhagic outcome, with
every 10ml increase resulting in an increased chance of a
higher grade of hemorrhagic outcome on an ordinal scale
(odds ratio 1.13, 95% CI 1.08–1.43, p < 0.001). More-
over, for every 1% increase in the volume of the E map
30% threshold lesion within the perfusion lesion, there
was a 1% increase in the likelihood of a PH1/1c or
PH2/2 (odds ratio, 2.01 95% CI 1.83–4.29, p < 0.001).
Neither Ktrans nor PS volumes predicted PH1/1c or
PH2/2 (p > 0.1). For example, if a patient had an
E >30% lesion volume that occupied >50% of the perfu-
sion lesion, the likelihood of PH1/1c was 40% (sensitiv-
ity 0.87, specificity 0.81) and that of PH2/2 5%
(sensitivity 0.75, specificity 0.83), whereas if only 70%
of the perfusion lesion was occupied, the likelihood of
PH1/1c was 70% (sensitivity 0.84, specificity 0.76) and
that of PH2/2 50% (sensitivity 0.78, specificity 0.86).
However, this result was not maintained in the MRI-
FIGURE 2: The likelihood of hemorrhagic transformation with the absolute E lesion volume restricted to the perfusion lesion
(DT3 seconds). With the increasing ratio of E lesion volume to perfusion lesion volume, there was an increased likelihood of
hemorrhage and an increase in the severity of hemorrhage. The overall accuracy of the predictive model was high and more
reliable than absolute E lesion volume alone. However, it was unusual for an individual patient to have a whole perfusion lesion
permeability E 30% lesion, and the results here represent data from a fitted risk model and represent associations rather than
true individual patient risk.
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FIGURE 3: An example of the E permeability map output (2nd column) and a threshold E permeable map constrained within the
perfusion lesion (3rd column), compared with a CTP CBF map (1st column), and the 24 hour CT/MRI (4th and 5th columns). On
the E permeability map, the red represents a very prolonged contrast signal, suggesting high permeability. In the threshold map
from the 3rd column, the blue area represents the E permeability >30% measure within the perfusion lesion (DT >3 seconds or
Tmax >6 seconds). The ability of the E permeability maps to predict HT was significantly increased when a threshold was set at
30% and the lesion volume limited as a fraction of the perfusion lesion. In the first row, there is a small E permeability lesion,
which predicted an HI1. The second row has a larger permeability lesion, but after a threshold was applied the fraction
of permeability compared with the perfusion lesion was small, and only HI2 was predicted. Next, in the 3rd row, a denser
permeability lesion is present, but again the volume was small and an HT2 was predicted. In the 4th row, there is a large,
severe permeability lesion, and the patient went on to have a PH2. In the 5th row, the patient has a large perfusion lesion and
large permeability lesion area, which developed into a PH2. The last row is an example of a patient with no permeability lesion
despite a large perfusion lesion and no HT. CBF = cerebral blood flow; CT = computed tomography; CTP = CT perfusion; DT =
delay time; E, extraction fraction; HI = hemorrhagic infarction; HT = hemorrhagic transformation; MRI = magnetic resonance
imaging; PH = parenchymal hematoma.
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only cohort (odds ratio 1.95 95%, CI 0.83–4.29,
p = 0.427).
In comparison to previously reported predictors of
HT, permeability derived from an E map at a threshold of
30% (AUC 0.91, R2 = 0.411, p < 0.001, Fig 3) was a
stronger predictor than ischemic core volume (AUC 0.62,
R2 = 0.341, p = 0.034, χ2 p = 0.181), very low CBV
(AUC 0.71, R2 = 0.249, p = 0.026, χ2 p = 0.382), and
severely delayed perfusion (AUC 0.74, Tmax 14 seconds,
R2 = 0.372, p = 0.011, χ2 p = 0.071). Next, E permeabil-
ity maps at a threshold of 30% were better at predicting
PH than ischemic core volume (AUC 0.77, R2 = 0.281,
p = 0.048, χ2 p = 0.249), very low CBV (AUC 0.74,
R2 = 0.187, p = 0.041, χ2 p = 0.124), reperfusion (AUC
0.75, R2 = 0.182, p = 0.037, χ2 p = 0.131), and severely
delayed perfusion (AUC 0.75, Tmax 14 seconds
R2 = 0.134, p = 0.037, χ2 p = 0.091). A combined model
with an E map lesion volume at a 30% threshold
restricted to within the perfusion lesion and ischemic core
volume was also highly accurate at predicting PH (AUC
0.92 R2 = 0.488, p < 0.001, χ2 p = 0.291), but not HT
(AUC 0.74, R2 = 0.143, p = 0.029, χ2 p = 0.491).
Discussion
From a large, multicenter, international database, we have
shown that permeability maps are a strong imaging predic-
tor of HT, including PH1 and PH2, in ischemic stroke
patients treated with intravenous alteplase. Additionally,
compared with previously described imaging predictors of
hemorrhage, E permeability was significantly more accu-
rate, sensitive, and specific at predicting hemorrhage.
Moreover, the extent of the E lesion confined within the
perfusion lesion was proportional to the severity of hemor-
rhage across the range of HI1, HI2, PH1, and PH2. Fur-
thermore, the predictive accuracy was very strong, with
AUC > 0.9. Not surprisingly, the E permeability maps
could not predict remote hemorrhage and were able to
predict hemorrhages only when they originated within the
acute perfusion lesion.
Previously identified markers of HT have insufficient
power to alter a treatment decision-making process and
have not been implemented in guidelines as contraindica-
tions to thrombolysis. The present study provides data to
propose a highly accurate predictor of HT likelihood using
the E permeability map at a threshold of 30% within the
perfusion deficit. Although the E permeability map and
threshold cannot predict remote hemorrhage, remote hem-
orrhage is much less common and probably reflects disor-
ders of fibrinogen production. There is the potential that
this measure could be used to alter treatment decision-
making and, possibly, the consent process. In patients with
a large E lesion, for example if a patient had a 60% risk of
a PH, this information can be used to inform patient fam-
ily discussions around expected outcomes and decision-
making or guide future clinical trials. Additionally,
E permeability measures could be useful in trials of HT or
PH prevention to isolate a group of patients at risk and
enrich the trial cohort.
Study limitations need to be acknowledged. Firstly,
although INSPIRE is a large, multisite study, in which
the sites are strongly encouraged to enroll consecutive
patients, the need for pretreatment multimodal CT and
follow-up MR, along with clinical data from several time
points, means that, practically, not all thrombolyzed
patients at the centers were included.29 Therefore,
despite the known baseline clinical and imaging charac-
teristics, some unknown patient cohort biases might have
been present, which we cannot taken into account. Sec-
ondly, the assessment of the follow-up hemorrhage might
have been affected by the use of CT in a proportion of
cases, and even in cases with MRI, not all had suscepti-
bility weighted imaging (SWI); therefore, some smaller
hemorrhages might have been missed. If a different post-
processing algorithm is used to derive the E measures,
then this method would need to be revalidated in a simi-
lar manner to the present study; however, the underlying
principles are likely to be the same, but might need dif-
ferent thresholds if processed with different algorithms.
Importantly, variations in motion correction might also
produce different study results, particularly for longer
scans, where motion becomes more likely. Next, CTP
acquisitions in the present study were of differing lengths
(≥45 seconds in length, but the majority were
>60 seconds). This might have led to variability in the
permeability measures from different centers, particularly
for the measures of Ktrans and PS. Lastly, we did not
include patients undergoing thrombectomy at the time
of the analysis because we were underpowered, and repli-
cation to adjust the statistical model is required.
In conclusion, the present study has identified that
permeability measures from CTP can accurately predict
HT in ischemic stroke patients treated with intravenous
alteplase alone. This technique could potentially be useful
in trials seeking to target ischemic stroke patients at high
risk of HT and might influence the calculation of throm-
bolysis risk–benefit ratio in individual patients in clinical
practice, especially if validated in a thrombectomy cohort.
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